AA
AMLX icon

ALPS Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

ALPS Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
112,447
+22,464
+25% +$347K 0.01% 519
2026
Q1 		$1.25M Sell
89,983
-189
-0.2% -$2.66K 0.01% 538
2025
Q4 		$1.09M Buy
+90,172
New +$1.22M 0.01% 541
2025
Q2 		– Sell
-67,597
Closed -$239K – 1029
2025
Q1 		$239K Buy
67,597
+12,167
+22% +$43.3K ﹤0.01% 952
2024
Q4 		$210K Buy
+55,430
New +$261K ﹤0.01% 969
2024
Q3 		– Sell
-90,357
Closed -$172K – 999
2024
Q2 		$172K Sell
90,357
-48,893
-35% -$94.8K ﹤0.01% 956
2024
Q1 		$395K Buy
139,250
+89,522
+180% +$1.17M ﹤0.01% 636
2023
Q4 		$732K Buy
49,728
+32
+0.1% +$490 0.01% 549
2023
Q3 		$910K Buy
49,696
+316
+0.6% +$6.68K 0.01% 490
2023
Q2 		$1.07M Buy
49,380
+5,724
+13% +$155K 0.01% 479
2023
Q1 		$1.28M Sell
43,656
-1,256
-3% -$43.6K 0.01% 393
2022
Q4 		$1.66M Buy
+44,912
New +$1.59M 0.01% 338

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

ALPS Advisors's AMLX Position: Q2 2026 in Review

ALPS Advisors increased its Amylyx Pharmaceuticals (AMLX) stake by 25% in Q2 2026, buying an estimated $347K and bringing the position to 112,447 shares worth $2.02M. The position accounts for 0.01% of the portfolio, ranked #519.

ALPS Advisors first reported a position in AMLX in Q4 2022 and has held it in 12 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • ALPS Advisors held 112,447 shares of Amylyx Pharmaceuticals worth $2.02M as of Q2 2026.
  • ALPS Advisors bought 22,464 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $347K.
  • Amylyx Pharmaceuticals made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #519 holding.
  • ALPS Advisors first reported a position in Amylyx Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.